Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis

Exclusion criteria

• . unrelieved abdominal pain caused by acute onset of pancreatitis or by other causes；
• . disease history of malignancy or currently suffering from any malignant tumor;
• . autoimmune diseases;
• . disease history of epilepsy or mental illness (e.g. schizophrenia, depression, mania, anxiety, etc.);
• . heart diseases: cardiomyopathy and myocarditis; structural heart diseases; coronary heart disease (acute coronary syndrome, myocardial infarction); pericardial disease; severe arrhythmias (severe tachycardia requiring pacemakers, severe rapid arrhythmias, and other arrhythmias beyond the control of medications) ; New York Heart Association (NYHA) classification heart function grading ≥III or Left Ventricular Ejection Fraction (LVEF) ≤50%;
• . poorly controlled diabetes (fasting blood glucose ≥11.1mmol/L);
• . with systolic blood pressure (SBP) \> 150mmHg and/or diastolic blood pressure (DBP) \> 100mmHg after treatment with a stable dose (at least 4 weeks) of antihypertensive drugs;
• . Aspartate transaminase (AST) or alanine transaminase (ALT) \> 2 × upper limit of normals (ULN);